DE60207277D1 - Bakterieller impfstoff - Google Patents

Bakterieller impfstoff

Info

Publication number
DE60207277D1
DE60207277D1 DE60207277T DE60207277T DE60207277D1 DE 60207277 D1 DE60207277 D1 DE 60207277D1 DE 60207277 T DE60207277 T DE 60207277T DE 60207277 T DE60207277 T DE 60207277T DE 60207277 D1 DE60207277 D1 DE 60207277D1
Authority
DE
Germany
Prior art keywords
attenuated
bacteria
enterotoxins
bacterial vaccine
provides strains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60207277T
Other languages
English (en)
Other versions
DE60207277T2 (de
Inventor
Arthur Keith Turner
Judith Greenwood
Jonathan Clive Stephens
Juliet Claire Beavis
Michael James Darsley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Holding Ltd
Original Assignee
Acambis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9921935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60207277(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acambis Research Ltd filed Critical Acambis Research Ltd
Publication of DE60207277D1 publication Critical patent/DE60207277D1/de
Application granted granted Critical
Publication of DE60207277T2 publication Critical patent/DE60207277T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60207277T 2001-09-11 2002-09-11 Bakterieller impfstoff Revoked DE60207277T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0121998.9A GB0121998D0 (en) 2001-09-11 2001-09-11 Attenuated bacteria useful in vaccines
GB0121998 2001-09-11
PCT/GB2002/004123 WO2003022306A2 (en) 2001-09-11 2002-09-11 Bacterial vaccine

Publications (2)

Publication Number Publication Date
DE60207277D1 true DE60207277D1 (de) 2005-12-15
DE60207277T2 DE60207277T2 (de) 2006-08-03

Family

ID=9921935

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60207277T Revoked DE60207277T2 (de) 2001-09-11 2002-09-11 Bakterieller impfstoff
DE60207278T Expired - Lifetime DE60207278T3 (de) 2001-09-11 2002-09-11 Attenuierte bakterien verwendbar als impfstoff

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60207278T Expired - Lifetime DE60207278T3 (de) 2001-09-11 2002-09-11 Attenuierte bakterien verwendbar als impfstoff

Country Status (10)

Country Link
US (4) US7943122B2 (de)
EP (2) EP1425037B1 (de)
AT (2) ATE308992T1 (de)
AU (2) AU2002321644B2 (de)
CA (2) CA2459586A1 (de)
DE (2) DE60207277T2 (de)
DK (2) DK1425038T4 (de)
ES (2) ES2256514T3 (de)
GB (1) GB0121998D0 (de)
WO (2) WO2003022307A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
WO2005017128A2 (en) * 2003-02-26 2005-02-24 University Of Massachusetts Improved reagents for recombinogenic engineering and uses thereof
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
EP1543836A1 (de) * 2003-12-17 2005-06-22 Berna Biotech AG Rekombinante Stamm von Vibrio cholerae und Impfstoff, der diesem Stamm enthält
WO2005113827A2 (en) * 2004-05-19 2005-12-01 THE UNITED STATES OF AMERICA AS REPRESENTED BY THESECRETARY OF THE ARMY, Walter REED ARMY INSTITUTE OF RESEARCH Construction of live attenuated shigella vaccine strains that express cfa/i antigens (cfab and cfae) and the b subunit of heat-labile enterotoxin (ltb) from enterotoxigenic e. coli
US9079945B2 (en) * 2005-01-11 2015-07-14 Naval Medical Research Center Adhesin as immunogen against enterotoxigenic Escherichia coli
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
WO2007089205A1 (en) * 2006-02-01 2007-08-09 Sbl Vaccin Ab Colonization factor (cf) antigens of enterotoxigenic escherichia coli in recombinant bacteria
AU2008270303A1 (en) * 2007-07-02 2009-01-08 Gotovax Ab Hybrid operon for expression of colonization factor (CF) antigens of enterotoxigenic escherichia coli
US9410157B2 (en) 2010-07-30 2016-08-09 Wisconsin Alumni Research Foundation Systems and methods for the secretion of recombinant proteins in gram negative bacteria
JP5985643B2 (ja) 2011-09-12 2016-09-06 スカンジナビアン バイオファーマ ホールディング アーベー 細胞表面上におけるｅｔｅｃｃｓ６抗原の提示を増大させるための方法およびその得られる産物
US9452205B2 (en) * 2012-09-24 2016-09-27 Montana State University Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use
CA2890380C (en) 2012-11-19 2021-11-30 The United States Of America As Represented By The Secretary Of The Navy Recombinant polypeptide construct comprising multiple enterotoxigenic escherichia coli fimbrial subunits
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
CA2966754A1 (en) 2014-11-05 2016-05-12 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
CN105063073A (zh) * 2015-09-16 2015-11-18 中国科学院南海海洋研究所 一种弧菌通用的基因敲除自杀载体及其应用
CA3095914A1 (en) * 2018-04-03 2019-10-10 University Of Maryland, Baltimore Enhanced shigella-enterotoxigenic e. coli multi-valent vaccine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58146596A (ja) 1982-02-25 1983-09-01 Takeda Chem Ind Ltd 組換えｄｎａ、それで形質転換させた微生物およびそれらの用途
US4935364A (en) * 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
SE9100556D0 (sv) 1991-02-26 1991-02-26 Holmgren Jan Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
KR100240182B1 (ko) 1991-03-05 2000-01-15 레슬리 제인 에드워즈 재조합 단백질을 발헨하는 약독해진 박테리아를 함유하는 백신
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US7404961B2 (en) * 1996-08-02 2008-07-29 The United States Of America As Represented By The Secretary Of The Army Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
SE9801852D0 (sv) 1998-05-26 1998-05-26 Sbl Vaccin Ab Method of producing thy A-strains of Vibro cholerae, suck strains and their use
SE515285C2 (sv) 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
WO2001019998A1 (en) 1999-09-15 2001-03-22 Mogam Biotechnology Research Institute Novel detoxified mutants of escherichia coli heat-labile enterotoxin
HUP0300297A3 (en) * 2000-04-20 2005-09-28 Univ Maryland Baltimore Baltim Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
WO2010048322A1 (en) * 2008-10-21 2010-04-29 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
US9327019B2 (en) * 2009-06-30 2016-05-03 Stc.Unm Attenuated enterohemorrhagic E. coli-based vaccine vector and methods relating thereto

Also Published As

Publication number Publication date
ATE308992T1 (de) 2005-11-15
EP1425037B1 (de) 2005-11-09
EP1425038B1 (de) 2005-11-09
US8318148B2 (en) 2012-11-27
ATE308991T1 (de) 2005-11-15
EP1425037A2 (de) 2004-06-09
WO2003022307A1 (en) 2003-03-20
AU2002321644B2 (en) 2008-03-13
CA2459586A1 (en) 2003-03-20
DK1425038T3 (da) 2006-03-27
DK1425038T4 (da) 2010-12-13
DK1425037T3 (da) 2006-03-27
US20040253710A1 (en) 2004-12-16
DE60207278D1 (de) 2005-12-15
ES2256515T3 (es) 2006-07-16
US7943122B2 (en) 2011-05-17
DE60207278T2 (de) 2006-08-10
CA2460025A1 (en) 2003-03-20
US20050054075A1 (en) 2005-03-10
EP1425038B2 (de) 2010-09-01
US20110200638A1 (en) 2011-08-18
DE60207277T2 (de) 2006-08-03
ES2256515T5 (es) 2011-02-25
WO2003022306A3 (en) 2003-06-26
WO2003022306A2 (en) 2003-03-20
ES2256514T3 (es) 2006-07-16
US20110189225A1 (en) 2011-08-04
GB0121998D0 (en) 2001-10-31
DE60207278T3 (de) 2011-05-05
US7951361B2 (en) 2011-05-31
EP1425038A1 (de) 2004-06-09
AU2002321652B2 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
ATE308991T1 (de) Bakterieller impfstoff
WO2002053189A3 (en) Immunogenic complex
FR11C0001I2 (fr) Vaccins combines contre neisseria meningitidis
ATE357249T1 (de) Auf bläschen basierendes impfstoff gegen chlamydia
WO2002009746A3 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
MA29459B1 (fr) Vaccins
NO20004781D0 (no) Svekkede bakterier anvendelige i vaksiner
WO2000037609A3 (en) Orally immunogenic bacterial enterotoxins expressed in transgenic plants
WO2002034773A3 (en) Streptococcal genes
HU0005010D0 (de)
DK1154791T3 (da) Neisseria-vaccinesammensætninger og fremgangsmåder
EP1908839A3 (de) Virulenzgene, Proteine und ihre Anwendung
NO20062469L (no) Streptococcus phocae vaksine
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine
EP1430025A4 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von bakteriellen infektionen
RU2002122063A (ru) Штам бактерий leptospira interrogans "митронов" серогруппы canicola для приготовления вакцины
WO2005021031A3 (en) Live attenuated bacterial vaccine
AU2001258579A1 (en) Virulence genes, proteins, and their use
DE60238554D1 (de) Vakzine gegen infektionskrankheiten
CY1117291T1 (el) Εμβολιο κατα του ροταϊου
RU2003122317A (ru) Средство, повышающее иммуногенные свойства столбнячного анатоксина
RU2001132094A (ru) Штамм бактерий Escherichia coli № 28 09:K99, используемый для изготовления вакцин и диагностических препаратов
RU99117153A (ru) Штамм бактерий pseudomonas aeruginosa 4762, используемый для изготовления вакцины против псевдомоноза пушных зверей
RU99117152A (ru) Штамм бактерий pseudomonas aeruginosa 4492, используемый для изготовления вакцины против псевдомоноза пушных зверей

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation